Drug Profile
Urological disorders immunotherapeutic - AmVac
Alternative Names: AMV 110; ProstaVacLatest Information Update: 29 May 2015
Price :
$50
*
At a glance
- Originator Vakcina Kft
- Developer AmVac
- Class Bacterial vaccines; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Benign prostatic hyperplasia; Prostatitis
Most Recent Events
- 29 May 2015 No recent reports on development identified - Phase-II for Benign prostatic hyperplasia and Prostatitis in Hungary (IM)
- 29 Feb 2012 AmVac's immunotherapeutic for urological disorders is available for partnering in USA, Japan. http://amvac.eu/v2/
- 05 Feb 2007 Phase-II clinical trials in Benign prostatic hyperplasia in Hungary (IM)